Contact Dr Alexey Larionov
Background
Initially educated as a medical doctor in Russia (in 1992), Dr Alexey Larionov became interested in translational biomedical research and completed a PhD studying mechanisms and markers of endocrine resistance in breast cancer (in 1997). Supported by the Royal Society grant, Alexey did his postdoctoral fellowship in Edinburgh University. Working with data-rich experimental methods (qPCR, microarrays, NGS) he became interested in data analysis and switched to bioinformatics. After completion of MSc in Applied Bioinformatics (2012, Cranfield University) Alexey worked as a bioinformatician in Cambridge University, focusing on NGS data analysis and heritable predisposition to cancer. Since 2021 Alexey is a Lecturer in Bioinformatics in Cranfield University.
Along with the research Dr Alexey Larionov is involved in teaching (supervision, lecturing and marking), and I am a Fellow of The Higher Education Academy (UK).
See more details at http://larionov.co.uk
Publications
Articles In Journals
- Larionov A, Fewings E, Redman J, Goldgraben M, Clark G, .... (2023). The Contribution of Germline Pathogenic Variants in Breast Cancer Genes to Contralateral Breast Cancer Risk in BRCA1/BRCA2/PALB2-Negative Women. Cancers, 15(2)
- Yngvadottir B, Andreou A, Bassaganyas L, Larionov A, Cornish AJ, .... (2022). Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases. Human Molecular Genetics, 31(17)
- Fewings E, Khoo Sert Kim S, Larionov A, Marker A, Giger O, .... (2021). Investigating the clinical, pathological and molecular profile of oncocytic adrenocortical neoplasms: a case series and literature review. Endocrine Oncology, 1(1)
- Goldgraben MA, Fewings E, Larionov A, Scarth J, Redman J, .... (2020). Genomic profiling of acute myeloid leukaemia associated with ataxia telangiectasia identifies a complex karyotype with wild‐type TP53 and mutant KRAS, G3BP1 and IL7R. Pediatric Blood & Cancer, 67(9)
- Fewings E, Ziemer M, Hörtnagel K, Reicherter K, Larionov A, .... (2019). Malta (MYH9 Associated Elastin Aggregation) Syndrome: Germline Variants in MYH9 Cause Rare Sweat Duct Proliferations and Irregular Elastin Aggregations. Journal of Investigative Dermatology, 139(10)
- Fewings E, Larionov A, Redman J, Goldgraben MA, Scarth J, .... (2018). Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. The Lancet Gastroenterology & Hepatology, 3(7)
- Larionov AA. (2018). Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. Frontiers in Oncology, 8(APR)
- Goldgraben M, Larionov A, Fewings E, Scarth J, Redman J, .... (2018). PO-061 Exploring heritable predisposition to paediatric rhabdomyosarcomas. ESMO Open, 3
- Flågeng MH, Larionov A, Geisler J, Knappskog S, Prestvik WS, .... (2017). Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers. The Journal of Steroid Biochemistry and Molecular Biology, 165(Pt B)
- Turnbull AK, Arthur LM, Renshaw L, Larionov AA, Kay C, .... (2015). Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer. Journal of Clinical Oncology, 33(20)
- Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, .... (2015). Personalization of loco-regional care for primary breast cancer patients (part 2). Future Oncology, 11(9)
- Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, .... (2015). Personalization of loco-regional care for primary breast cancer patients (part 1). Future Oncology, 11(9)
- López-Knowles E, Wilkerson PM, Ribas R, Anderson H, Mackay A, .... (2015). Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer. Breast Cancer Research, 17(1)
- Arthur LM, Turnbull AK, Webber VL, Larionov AA, Renshaw L, .... (2014). Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy. Cancer Research, 74(19)
- Sokolenko AP, Bulanova DR, Iyevleva AG, Aleksakhina SN, Preobrazhenskaya EV, .... (2014). High prevalence ofGPRC5Agermline mutations inBRCA1-mutant breast cancer patients. International Journal of Cancer, 134(10)
- Sims AH, Larionov AA, Harrison DJ & Katz E. (2013). Use of Microarray Analysis to Investigate EMT Gene Signatures. Methods in Molecular Biology, 1046
- Kuligina ES, Sokolenko AP, Mitiushkina NV, Abysheva SN, Preobrazhenskaya EV, .... (2013). Value of bilateral breast cancer for identification of rare recessive at-risk alleles: evidence for the role of homozygous GEN1 c.2515_2519delAAGTT mutation. Familial Cancer, 12(1)
- Turnbull AK, Kitchen RR, Larionov AA, Renshaw L, Dixon JM, .... (2012). Direct integration of intensity-level data from Affymetrix and Illumina microarrays improves statistical power for robust reanalysis. BMC Medical Genomics, 5(1)
- Sokolenko AP, Iyevleva AG, Preobrazhenskaya EV, Mitiushkina NV, Abysheva SN, .... (2012). High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia. International Journal of Cancer, 130(12)
- Miller WR, Larionov A, Anderson TJ, Evans DB & Dixon JM. (2012). Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. The Pharmacogenomics Journal, 12(1)
- Miller WR & Larionov AA. (2012). Understanding the mechanisms of aromatase inhibitor resistance. Breast Cancer Research, 14(1)
- Kuligina ES, Sokolenko AP, Mitiushkina NV, Abysheva SN, Preobrazhenskaya EV, .... (2012). Abstract 74: Value of bilateral breast cancer for identification of rare recessive at-risk alleles: evidence for the role of homozygous GEN1 c.2515_2519delAAGTT mutation.. Cancer Epidemiology, Biomarkers & Prevention, 21(11_Supplement)
- Flågeng MH, Larionov A, Geisler J, Dixon JM, Lønning PE, .... (2012). Abstract P6-04-06: Inverse regulation of Neuregulin1 and HER-3 during treatment with aromatase inhibitors of estrogen receptor-positive breast cancer. Cancer Research, 72(24_Supplement)
- Larionov A, Turnbull A, Sims A, Renshaw L, Kay C, .... (2012). Abstract P3-06-23: Predicting response to neoadjuvant letrozole. Cancer Research, 72(24_Supplement)
- Miller WR & Larionov A. (2011). Molecular effects of oestrogen deprivation in breast cancer. Molecular and Cellular Endocrinology, 340(2)
- Miller WR & Larionov AA. (2011). Bridging the Gap Between Translational Research and Clinical Application. JNCI Monographs, 2011(43)
- Miller WR & Larionov A. (2010). Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole. Breast Cancer Research, 12(4)
- Hrstka R, Nenutil R, Fourtouna A, Maslon MM, Naughton C, .... (2010). The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene, 29(34)
- Miller WR, Krause A, Larionov A, Evans DB, Anderson TJ, .... (2010). Genes discriminating between breast cancers responsive or resistant to the aromatase inhibitor, letrozole. European journal of Clinical and Medical Oncology, 2(2)
- Larionov AA & Miller WR. (2009). Challenges in defining predictive markers for response to endocrine therapy in breast cancer. Future Oncology, 5(9)
- Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, .... (2009). Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings of the National Academy of Sciences, 106(33)
- Larionov A, Faratian D, Caldwell H, Sims A, Fawkes A, .... (2009). Genes Regulated by miRNA in Endocrine-Resistant Breast Tumours.. Cancer Research, 69(24_Supplement)
- Larionov A, Faratian D, Caldwell H, Sims A, Fawkes A, .... (2009). Gene Expression Profiles of Endocrine Resistant Breast Tumours.. Cancer Research, 69(24_Supplement)
- Larionov A, Faratian D, Caldwell H, Sims A, Fawkes A, .... (2009). miRNA Profiling of Endocrine-Resistant Breast Tumours.. Cancer Research, 69(24_Supplement)
- Miller WR, Larionov AA, Renshaw L, Anderson TJ, White S, .... (2007). Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenetics and Genomics, 17(10)
- Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, .... (2007). Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Research, 9(3)
- Miller WR, Larionov A, Renshaw L, Anderson TJ, White S, .... (2007). Aromatase inhibitors—Gene discovery. The Journal of Steroid Biochemistry and Molecular Biology, 106(1-5)
- Tomlinson VAL, Newbery HJ, Wray NR, Jackson J, Larionov A, .... (2005). Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours. BMC Cancer, 5(1)
- Larionov A, Krause A & Miller W. (2005). A standard curve based method for relative real time PCR data processing. BMC Bioinformatics, 6(1)
- Miller WR, Renshaw L, Larionov A, Anderson TJ, White S, .... (2005). Prediction of hormone response in breast cancer by microarray analysis of sequential tumour biopsies from patients receiving neoadjuvant therapy with letrozole. Journal of Clinical Oncology, 23(16_suppl)
- Berstein LM, Kovalevskij A, Larionov A, Tsyrlina E, Vasilyev D, .... (2003). Aromatase activity in receptor negative breast and endometrial cancer. Experimental Oncology, 25(3)
- Larionov AA, Berstein LM & Miller WR. (2002). Local uptake and synthesis of oestrone in normal and malignant postmenopausal breast tissues. The Journal of Steroid Biochemistry and Molecular Biology, 81(1)
- Berstein L, Larionov A, Poroshina T, Zimarina T & Leenman E. (2002). Aromatase (CYP19) expression in tumor-infiltrating lymphocytes and blood mononuclears. Journal of Cancer Research and Clinical Oncology, 128(3)
- Berstein L, Maximov S, Gershfeld E, Meshkova I, Gamajunova V, .... (2002). Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects. European Journal of Obstetrics & Gynecology and Reproductive Biology, 105(2)
- Bershtein LM, Maksimov SI, Gershfel'd ED, Gamaiunova VB, Tsyrlina EV, .... (2001). Neoadjuvant use of the aromatase inhibitor letrozole in uterine cancer: endocrine and clinical effects. Voprosy onkologii, 47(5)
- Larionov AA, Poroshina TE, Zimarina TS, Leenman EE & Bershtein LM. (2000). Aromatase (estrogen synthetase) gene expression in human leukocytes. Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova / Rossiiskaia akademiia nauk, 86(1)
- Berstein LM, Larionov AA, Pauley RJ, Chernitsa OI, Semiglazov VF, .... (1999). Aromatase gene expression and its modifying factors in breast tumor tissue. Voprosy onkologii, 45(5)
- Berstein LM, Larionov AA, Chernitsa OI, Kolesnik OS & Manikhas AG. (1998). Aromatase activity and its gene expression in tumor tissue of smokers and non-smokers with breast cancer. Voprosy onkologii, 44(6)
- Larionov AA, Uporov AV, Semiglazov VF & Berstein LM. (1998). Correlation between tumor tissue aromatase, histological pattern and reproductive status in patients with breast cancer. Voprosy onkologii, 44(1)
- Bershtein LM, Poroshina TE, Larionov AA & Zimarina TS. (1998). Metabolism of the androgenic precursor androstenedione and effects of aromatase inhibitors in cultured blood lymphocytes. Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova / Rossiiskaia akademiia nauk, 84(11)
- Berstein LM, Poroshina TE, Zimarina TS, Larionov AA, Kovalenko IG, .... (1998). Ability of lymphocytes infiltrating breast-cancer tissue to convert androstenedione. International Journal of Cancer, 77(4)
- Bershtein LM, Poroshina TE, Zimarina TS, Larionov AA & Uporov AV. (1997). Conversion of androstenedione in the lymphocytes infiltrating the breast tumor tissue. Biulleten' eksperimental'noi biologii i meditsiny, 124(10)
- Bershtein LM, Poroshina TE, Larionov AA, Zimarina TS & Kryukova OG. (1997). Dexamethasone and dibutyryl-cAMP stimulate androstenedione conversion in human blood lymphocytes. Doklady Akademii Nauk, 352(2)
- Bershtein LM, Poroshina TE, Zimarina TS, Larionov AA & Uporov AV. (1997). Androstenedione conversion in lymphocytes infiltrating breast tumor tissue. Bulletin of Experimental Biology and Medicine, 124(4)
- Berstein LM, Larionov AA, Kyshtoobaeva AS, Pozharisski KM, Semiglazov VF, .... (1996). Aromatase in breast cancer tissue ? localization and relationship with reproductive status of patients. Journal of Cancer Research and Clinical Oncology, 122(8)
- Berstein LM, Kovalenko IG, Tsyrlina YV & Larionov AA. (1996). Catecholamine excretion in smoking female breast cancer patients: A possible relation to the mechanisms of hormonal carcinogenesis. Experimental Oncology, 18(2)
- Bershtein LM, Poroshina TE, Tsyrlina EV, Gamaiunova VB, Kovalenko IG, .... (1996). Correlation of lymphocytic infiltration of tumor tissue with the hormonal and metabolic state in patients with breast cancer. Voprosy onkologii, 42(5)
- Berstein LM, Larionov AA, Krjukova OG, Kochev VA & Semiglasov VF. (1996). Investigation of aromatase activity in human muscle tissue. Voprosy Meditsinskoj Khimii, 42(1)
- Berstein LM, Kovalenko IG, Tsyrlina YV & Larionov AA. (1996). Catecholamine excretion in smoking female breast cancer patients: A possible relation to the mechanisms of hormonal carcinogenesis. EXPERIMENTAL ONCOLOGY, 18(3)
- Bershtein LM, Larionov AA, Kryshtoobaeva AS, Pozharisskii KM & Semiglazov VF. (1995). Aromatase activity in breast cancer tissue: the role of a cellular substrate. Biulleten' eksperimental'noi biologii i meditsiny, 120(10)
- Bershtein LM, Larionov AA, Kyshtoobaeva AS, Pozharisskii KM & Semiglazov VF. (1995). Activity of aromatase in breast cancer tissue: Role of the cell substrate. Bulletin of Experimental Biology and Medicine, 120(4)
- Bershteǐn LM, Tsyrlina EV, Semiglazov VF, Larionov AA, Kovalenko IG, .... (1994). Adipose and lean body mass in obese pre- and post-menopausal patients with breast cancer: the modifying role of smoking. Voprosy Onkologii, 40(7-12)
- Bershtein LM, Larionov AA & Kryukova OG. (1994). Androstenedione conversion in human peripheral blood lymphocytes. Bulletin of Experimental Biology and Medicine, 117(5)
- Khirmanov VN, Kireenkov IS, Berkovich OA, Larionov AA, Kornilov NV, .... (1993). Changes in the concentration of atrial hormone in hypertensive crises. Klinicheskaya Meditsina, 71(3)
- 536490 - Citation not available
Conference Papers
- Larionov A, Fewings E, Redman J, Goldgraben M, Hadfield J, .... (2018). Using whole exome sequencing to explore germline variation in BRCA1/BRCA2/PALB2 negative contralateral breast cancers from the Women's Environmental Cancer and Radiation Epidemiology (WECARE) study
- Fewings ER, Larionov A, Redman J, Goldgraben M, Hardwick R, .... (2018). Exploring germline variation in known cancer predisposing genes amongst CDH1-negative hereditary diffuse gastric cancer families
- Arthur L, Turnbull A, Webber V, Larionov A, Renshaw L, .... (2014). Molecular Changes in Lobular Breast Cancers in Response to Neoadjuvant Letrozole
- Turnbull AK, Webber V, Arthur LM, Larionov AA, Renshaw L, .... (2014). 7LBA A 4 gene model can identify ER+HER2+ breast cancers unlikely to respond to neoadjuvant endocrine therapy
- Webber V, Turnbull AK, Larionov AA, Renshaw L, Sims AH, .... (2013). Abstract P5-09-01: Comprehensive gene assessment of estrogen receptor positive breast cancer reveals that HER2 plays an important role in resistance to neoadjuvant letrozole
- Turnbull AK, Arthur L, Webber V, Larionov AA, Renshaw L, .... (2013). Abstract PD3-2: Accurate and robust prediction of clinical response to aromatase inhibitors by two weeks of neoadjuvant breast cancer treatment
- Turnbull AK, Larionov AA, Renshaw L, Kay C, Sims AH, .... (2012). Abstract P6-04-09: Lack of response to aromatase inhibitors involves distinct mechanisms
- Webber V, Turnbull AK, Larionov AA, Sims AH, Harrison D, .... (2012). Abstract P6-04-10: Comprehensive gene and protein assessment of the role of Her2 in the response to neoadjuvant Letrozole suggests patients without amplification may also benefit from anti-Her2 treatment
- Larionov A, Turnbull A, Sims A, Renshaw L, Kay C, .... (2012). Predicting response to neoadjuvant letrozole
- Flageng MH, Larionov A, Geisler J, Dixon JM, Lonning PE, .... (2012). Inverse regulation of Neuregulinl and HER-3 during treatment with aromatase inhibitors of estrogen receptor positive breast cancer
- Liu MC, Dixon JM, Xuan JJ, Riggins RB, Chen L, .... (2011). S1-8: Molecular Signaling Distinguishes Early ER Positive Breast Cancer Recurrences Despite Adjuvant Tamoxifen.
- Knowles EL, Anderson H, Mackay A, Ghazoui Z, Larionov A, .... (2011). STUDY OF DNA GAINS AND LOSSES IN TUMOURS OF BREAST CANCER (BC) PATIENTS RECEIVING NEO-ADJUVANT AROMATASE INHIBITOR (AI) TREATMENT
- Larionov A, Reis-Filho JS, Lambros MBK, Sproul D & Dixon JM. (2010). Abstract P4-02-03: Gene Copy Number Alterations Related to mRNA and miRNA Expression in Endocrine Resistant Breast Cancers
- Flågeng MH, Knappskog S, Larionov A, Geisler J, Dixon M, .... (2010). Abstract P4-02-02: Epidermal Growth Factor Receptors (ErbB/HER) and the Ligand Neuregulin 1 (NRG1) Increase in Breast Tumors during Short Time Endocrine Treatment
- Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, .... (2009). Gene Expression Profiles Differentiating Between Breast Cancers Clinically Responsive or Resistant to Letrozole
- Anderson H, A'Hern R, Salter J, Hills M, Detre S, .... (2009). Early Acquired Resistance to Endocrine Therapy: Extending the Neoadjuvant Model
- Larionov A, Faratian D, Caldwell H, Sims A, Fawkes A, .... (2009). miRNA Profiling of Endocrine-Resistant Breast Tumours.
- Larionov A, Faratian D, Caldwell H, Sims A, Fawkes A, .... (2009). Genes Regulated by miRNA in Endocrine-Resistant Breast Tumours
- Larionov A, Faratian D, Caldwell H, Sims A, Fawkes A, .... (2009). Gene Expression Profiles of Endocrine Resistant Breast Tumours.
- Miller WR, Larionov A, Anderson TJ, Walker JR, Krause A, .... (2008). Predicting response and resistance to endocrine therapy
- Katz E, Faratian D, Bartlett JMS, MacLeod K, Pedersen H, .... (2008). C35 overexpression defines subsets of human breast cancer and its immunoreceptor tyrosine-based activation motif represents a novel treatment target
- Larionov A, Murray E, Miller WR & Dixon JM. (2007). O-45 Reproducibility and interpretation of quantitative gene expression measurements in breast cancer biopsies
- Miller WR, Larionov A, Evans DB & Dixon M. (2007). Early changes in expression of oestrogen-regulated and proliferation genes illustrate heterogeneity in primary resistance to letrozole
- Larionov A, Murray E, Evans DB, Miller WR & Dixon JM. (2007). Changes in cyclins' and CDKs' mRNA expression during neoadjuvant treatment with letrozole
- Miller W, Renshaw L, Larionov A, Anderson T, White S, .... (2006). Using changes in gene expression as assessed by microarray analysis of sequential tumour biopsies to predict response to neoadjuvant therapy with letrozole
- Larionov A, Miller W, White S, Evans DB, Krause A, .... (2006). High density micro-arrays do not accurately reflect the decrease in MK167 in breast cancers during treatment with the aromatase inhibitors anastrozole and letrozole.
- Kendall A, Mackay A, Dexter T, Fenwick K, Harper-Wynne C, .... (2006). Studies of the estrogen dependence of gene expression in normal postmenopausal breast tissue in vivo.
- Miller WR, Anderson TJ, White S, Larionov A, Murray J, .... (2005). Aromatase inhibitors: Cellular and molecular effects
- Larionov AA, Dixon JM, Krause A, Evans DB & Miller WR. (2005). Validation of reference genes for relative real time PCR to study hormone-dependent gene expression in breast cancer biopsies
- Larionov AA, Dixon JM, White S, Anderson TJ & Miller WR. (2005). Repeatability and sources of uncertainty in relative real time PCR gene expression measurements in breast cancer biopsies
- Miller WR, Renshaw L, Larionov A, Anderson TJ, White S, .... (2005). Prediction of hormone response in breast cancer by microarray analysis of sequential tumour biopsies from patients receiving neoadjuvant therapy with letrozole.
- Miller WR, Krause A, Evans DB, Renshaw L, Marray J, .... (2005). Phenotypes for endocrine resistance can be identified by RNA microarray of sequential biopsies and are more variable than those predicting for tumour response.
- Miller WR & Larionov A. (2004). Aromatase 2004, Edinburgh, UK, 6-8 September 2004
- Miller WR, Renshaw L, Murray J, Larionov A, Anderson TJ, .... (2004). Microarray analysis of sequential tumour biopsies from patients receiving neoadjuvant therapy is able to distinguish sub-populations of breast cancers with differential response to the aromatase inhibitor, letrozole.
- Larionov AA, Vasyliev DA, Mason JI, Howie AF, Berstein LM, .... (2003). Aromatase in skeletal muscle
- Berstein L, Larionov A, Edamatsu H & Itoh H. (1999). Expression of the genes of adenylate cyclase (AC) G-protein subunits in breast cancer (BC) tissue: connection with estrogen-dependency?
- Berstein LM, Poroshina TE, Zimarina TS, Larionov AA & Uporov AV. (1998). Androstenedione (A) conversion in lymphocytes infiltrating breast cancer (BC) tissue
- Berstein L, Poroshina T, Tsyrtina E, Gamajunova V, Chemitsa O, .... (1997). Tumor lymphocytic infiltration, hormonal-metabolic status and aromatase gene expression in breast cancer
Books
- Larionov AA. (2016). Novel Translational Research of Neo-adjuvant Endocrine Therapy In Personalized Treatment of Breast Cancer. Springer Japan.
- Larionov AA & Miller WR. (2015). Prediction of Response to Aromatase Inhibitors in Breast Cancer In Resistance to Targeted Anti-Cancer Therapeutics (8). Springer International Publishing.
